5-溴-2-甲基吲哚-3-羧醛 | 17826-09-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 5-溴-2-甲基吲哚-3-羧醛
• 英文名称: 5-bromo-2-methyl-1H-indole-3-carbaldehyde
• 英文别名: 2-methyl-5-bromo-3-formylindole；5-Brom-2-methyl-indol-3-carbaldehyd；5-bromo-2-methyl-indole-3-carbaldehyde；5-bromo-2-methyl-3-formylindol；5-bromo-2-methyl-indole-3-carboxaldehyde
• CAS: 17826-09-4
• 化学式: C₁₀H₈BrNO
• 分子量: 238.084
• InChiKey: VRSRWYBZDMNUAK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  32.9
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5-溴-2-甲基吲哚-3-羧醛 在 sodium tetrahydroborate 、 N-溴代丁二酰亚胺(NBS) 、 sodium hydride 、 三苯基膦 、 三氟乙酸 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 11.25h， 生成 N-((5-bromo-2-methyl-1(phenylsulfonyl)-1H-indol-3-yl)methyl)hydroxylamine
  参考文献：
  名称：

  Discovery and Refinement of a New Structural Class of Potent Peptide Deformylase Inhibitors

  摘要：

  New classes of antibiotics are urgently needed to counter increasing levels of pathogen resistance. Peptide deformylase (PDF) was originally selected as a specific bacterial target, but a human homologue, the inhibition of which causes cell death, was recently discovered. We developed a dual-screening strategy for selecting highly effective compounds with low inhibition effect against human PDF. We selected a new scaffold in vitro that discriminated between human and bacterial PDFs. Analyses of structure-activity relationships identified potent antibiotics such as 2-(5-bromo-1H-indol-3-yl)-N-hydroxyacetamide (6b) with the same mode of action in vivo as previously identified PDF inhibitors but without the apoptotic effects of these inhibitors in human cells.

  DOI：

  10.1021/jm060910c
• 作为产物：
  描述：

  2-甲基吲哚-3-甲醛 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 二氯甲烷 为溶剂， 反应 0.25h， 以93%的产率得到5-溴-2-甲基吲哚-3-羧醛
  参考文献：
  名称：

  Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents

  摘要：

  提供了作为化疗和化学预防剂有用的新化合物。这些化合物是吲哚-3-甲醇代谢物的类似物，其中化合物的结构和取代基被选择以增强化合物的整体功效，特别是在治疗活性、口服生物利用度、长期安全性、患者耐受性和治疗窗口方面。这些化合物不仅在癌症治疗中有用，而且在癌症预防中也有用。一类首选的新化合物具有以下结构式（I） 1 其中R 1 、R 2 、R 3 、R 4 、R 5 、R 6 、R 7 、R 8 、R 9 、R 10 、R 11 和R 12 在此定义。还提供了药物组合物，以及合成和使用方法。

  公开号：

  US20040043965A1

文献信息

• Direct construction of carbazoles from 2-methyl-indole-3-carbaldehydes and enals
  作者：Dehai Liu、Jie Huang、Zhenqian Fu、Wei Huang

  DOI：10.1039/c9gc00064j

  日期：——

  The direct and rapid construction of carbazoles was achieved via the reaction of 2-methyl-indole-3-carbaldehydes with enals promoted by LiCl/DBU in a single operation. This mild and green reaction proceeds through a [4 + 2] cycloaddition/dehydration/oxidative aromatization cascade to generate carbazoles in good to excellent yields. The reaction features mild reaction conditions, a broad substrate scope

  通过2-甲基-吲哚-3-甲醛与LiCl / DBU促进的烯醛在一次操作中的反应即可直接快速构建咔唑。这种温和而绿色的反应通过[4 + 2]环加成/脱水/氧化芳构化级联进行，从而生成咔唑，收率好至极佳。该反应具有温和的反应条件，广泛的底物范围和出色的官能团耐受性，使用O 2（1 atm）作为唯一氧化剂，并提供H 2 O作为唯一的副产物。更重要的是，仅需一步就可以从得到的咔唑生成80％收率的重要的生物活性化合物4-氟喹咔唑。
• Chemical uncouplers for the treatment of obesity
  申请人：——

  公开号：US20040138301A1

  公开（公告）日：2004-07-15

  This invention relates to chemical uncouplers with a broader safety window making the use of them in treating obesity and, consequently, in the treatment of obesity related diseases and conditions such as atherosclerosis, hypertension, diabetes, especially type 2 diabetes (NIDDM (non-insulin dependent diabetes mellitus)), impaired glucose tolerance, dyslipidemia, coronary heart disease, gallbladder disease, osteoarthritis and various types of cancer such as endometrial, breast, prostate and colon cancers and the risk for premature death as well as other conditions, such as diseases and disorders, which conditions are improved by an increase in mitochondrial respiration, more attractive.

  这项发明涉及一种化学解偶联剂，它具有更宽的安全窗口，使其在治疗肥胖症以及因此引发的相关疾病和状况，如动脉硬化、高血压、糖尿病（尤其是2型糖尿病（非胰岛素依赖型糖尿病））、葡萄糖耐量受损、血脂异常、冠心病、胆结石病、骨关节炎以及子宫内膜、乳房、前列腺和结肠等各种癌症以及过早死亡的风险等方面更具吸引力。此外，还包括其他通过增加线粒体呼吸得到改善的条件、疾病和紊乱。
• [EN] THERAPEUTIC AGENTS I<br/>[FR] AGENTS THERAPEUTIQUES I
  申请人：ASTRAZENECA AB

  公开号：WO2005066132A1

  公开（公告）日：2005-07-21

  Compounds of formula(I), processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders, and pharmaceutical compositions containing them.

  化合物的化学式(I)，制备这种化合物的方法，它们在治疗肥胖、精神障碍、认知障碍、记忆障碍、精神分裂症、癫痫以及相关疾病，以及神经系统疾病如痴呆症、多发性硬化症、帕金森病、亨廷顿舞蹈症、阿尔茨海默病和与疼痛相关的疾病中的应用，以及含有它们的药物组合物。
• Analogs of Indole-3-Carbinol Metabolites as Chemotherapeutic and Chemopreventive Agents
  申请人：JONG Ling

  公开号：US20090023796A1

  公开（公告）日：2009-01-22

  Novel compounds useful as chemotherapeutic and chemopreventive agents are provided. The compounds are analogs of indole-3-carbinol metabolites wherein the structures and substituents of the compounds are selected to enhance the compounds' overall efficacy, particularly with respect to therapeutic activity, oral bioavailability, long-term safety, patient tolerability, and therapeutic window. The compounds are useful not only in treatment of cancer but also in prevention of cancer. One preferred class of the novel compounds has the structure of formula (IV) wherein: R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 5A , R 6A , R 7A , R 8A , R 22 and R 23 are defined herein. Pharmaceutical compositions are provided as well, as are methods of synthesis and use.

  提供了一种作为化疗和化学预防剂的新化合物。这些化合物是吲哚-3-甲醇代谢产物的类似物，其中这些化合物的结构和取代基被选择以增强这些化合物的整体功效，特别是治疗活性、口服生物利用度、长期安全性、患者耐受性和治疗窗口方面的功效。这些化合物不仅在癌症治疗方面有用，而且在癌症预防方面也有用。其中一类优选的新化合物具有公式（IV）的结构，其中：R1、R2、R3、R4、R5、R6、R7、R8、R5A、R6A、R7A、R8A、R22和R23在此被定义。此外，还提供了制药组合物、合成和使用方法。
• Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventative agents
  申请人：SRI International

  公开号：EP1623985A2

  公开（公告）日：2006-02-08

  Novel compounds useful as chemotherapeutic and chemopreventative agents are provided. The compounds are analogs of indole-3-carbinol metabolites wherein the structures and substituents of the compounds are selected to enhance the compounds' overall efficacy, particularly with respect to therapeutic activity, oral bioavailability, long-term safety, patient tolerability, and therapeutic window. The compounds are useful not only in treatment of cancer but also in prevention of cancer. One preferred class of the novel compounds has the structure of formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are defined herein. Pharmacetical compositions are provided as well, as are methods of synthesis and use.

  本研究提供了可用作化疗和化疗预防剂的新型化合物。这些化合物是吲哚-3-甲醇代谢物的类似物，其中化合物的结构和取代基的选择是为了提高化合物的整体疗效，特别是在治疗活性、口服生物利用度、长期安全性、患者耐受性和治疗窗口方面。这些化合物不仅可用于治疗癌症，还可用于预防癌症。一类优选的新型化合物具有式 (I) 结构，其中 R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11 和 R12 在此定义。此外，还提供了药用组合物以及合成和使用方法。